4D Molecular Therapeutics(US:FDMT)2025-05-15 07:504D-150 Product & Clinical Development - 4D-150 is designed to disrupt the global market for retinal vascular diseases and improve patient outcomes[9, 11, 19, 29, 39, 44] - 4D-150 has received Regenerative Medicine Advanced Therapy (RMAT) designation for both wet AMD and DME[8] - 4D-150 Phase 3 4FRONT global registration program topline data from wet AMD pivotal trials is expected in H2 2027[10, 12, 20, 30, 41, 46] - Phase 1/2a data showed a 83% reduction in mean annual injections post 4D-150 in recently diagnosed patients, and a 94% reduction in Phase 2b populations[28] - In wet AMD patients, treatment-related 1+ vitreous cells at a single timepoint were observed in 2 of 71 patients, representing 2.8%[32, 34] - In DME patients, there was no intraocular inflammation at any timepoint at any dose level[35] Market Opportunity & Financials - The global market for retinal vascular diseases is $17 billion+ and growing[10, 12, 20, 30, 41, 46] - The company had $458 million cash as of March 31, 2025, providing runway into 2028[58] 4FRONT Phase 3 Trial Design - The 4FRONT Phase 3 trials are global, multicenter, randomized, double-masked, aflibercept Q8W comparator-controlled studies[47, 50] - The trials aim for noninferiority to enable global registration in wet AMD[47, 50]